95 related articles for article (PubMed ID: 15246729)
1. Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro.
Zhan X; Dravid G; Ye Z; Hammond H; Shamblott M; Gearhart J; Cheng L
Lancet; 2004 Jul 10-16; 364(9429):163-71. PubMed ID: 15246729
[TBL] [Abstract][Full Text] [Related]
2. Comparative characteristics of three human embryonic stem cell lines.
Lee JB; Kim JM; Kim SJ; Park JH; Hong SH; Roh SI; Kim MK; Yoon HS
Mol Cells; 2005 Feb; 19(1):31-8. PubMed ID: 15750337
[TBL] [Abstract][Full Text] [Related]
3. Early-outgrowth of endothelial progenitor cells can function as antigen-presenting cells.
Asakage M; Tsuno NH; Kitayama J; Kawai K; Okaji Y; Yazawa K; Kaisaki S; Osada T; Watanabe T; Takahashi K; Nagawa H
Cancer Immunol Immunother; 2006 Jun; 55(6):708-16. PubMed ID: 16133110
[TBL] [Abstract][Full Text] [Related]
4. Human embryonic stem cells have a unique epigenetic signature.
Bibikova M; Chudin E; Wu B; Zhou L; Garcia EW; Liu Y; Shin S; Plaia TW; Auerbach JM; Arking DE; Gonzalez R; Crook J; Davidson B; Schulz TC; Robins A; Khanna A; Sartipy P; Hyllner J; Vanguri P; Savant-Bhonsale S; Smith AK; Chakravarti A; Maitra A; Rao M; Barker DL; Loring JF; Fan JB
Genome Res; 2006 Sep; 16(9):1075-83. PubMed ID: 16899657
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin Decreases the Expression of CD133 and Influences the Differentiation Potential of Human Embryonic Stem Cells.
Kallas-Kivi A; Trei A; Maimets T
Stem Cells Int; 2016; 2016():1580701. PubMed ID: 27247576
[TBL] [Abstract][Full Text] [Related]
6. Mesoderm is committed to hemato-endothelial and cardiac lineages in human embryoid bodies by sequential exposure to cytokines.
Zhu MX; Zhao JY; Chen GA
Exp Cell Res; 2013 Jan; 319(1):21-34. PubMed ID: 23041209
[TBL] [Abstract][Full Text] [Related]
7. A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies.
Ng ES; Davis R; Stanley EG; Elefanty AG
Nat Protoc; 2008; 3(5):768-76. PubMed ID: 18451785
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells.
Yang L; Dybedal I; Bryder D; Nilsson L; Sitnicka E; Sasaki Y; Jacobsen SE
J Immunol; 2005 Jan; 174(2):752-7. PubMed ID: 15634895
[TBL] [Abstract][Full Text] [Related]
9. 'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells.
Wang C; Liu J; Li W
Cell Prolif; 2023 Apr; 56(4):e13425. PubMed ID: 36855955
[TBL] [Abstract][Full Text] [Related]
10. The Immune-Modulatory Properties of iPSC-Derived Antigen-Presenting Cells.
Ackermann M; Dragon AC; Lachmann N
Transfus Med Hemother; 2020 Dec; 47(6):444-453. PubMed ID: 33442339
[TBL] [Abstract][Full Text] [Related]
11. Human-induced pluripotent stem cell-derived macrophages and their immunological function in response to tuberculosis infection.
Hong D; Ding J; Li O; He Q; Ke M; Zhu M; Liu L; Ou WB; He Y; Wu Y
Stem Cell Res Ther; 2018 Feb; 9(1):49. PubMed ID: 29482598
[TBL] [Abstract][Full Text] [Related]
12. Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.
Chhabra A
Stem Cell Rev Rep; 2017 Dec; 13(6):757-773. PubMed ID: 28918520
[TBL] [Abstract][Full Text] [Related]
13. Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy.
Chhabra A
Front Immunol; 2017; 8():993. PubMed ID: 28868053
[TBL] [Abstract][Full Text] [Related]
14. Hurdles to clinical translation of human induced pluripotent stem cells.
Neofytou E; O'Brien CG; Couture LA; Wu JC
J Clin Invest; 2015 Jul; 125(7):2551-7. PubMed ID: 26132109
[TBL] [Abstract][Full Text] [Related]
15. Human dental pulp stem cells (hDPSCs): isolation, enrichment and comparative differentiation of two sub-populations.
Pisciotta A; Carnevale G; Meloni S; Riccio M; De Biasi S; Gibellini L; Ferrari A; Bruzzesi G; De Pol A
BMC Dev Biol; 2015 Mar; 15():14. PubMed ID: 25879198
[TBL] [Abstract][Full Text] [Related]
16. Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
Sachamitr P; Hackett S; Fairchild PJ
Front Immunol; 2014; 5():176. PubMed ID: 24860566
[TBL] [Abstract][Full Text] [Related]
17. Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application.
Kim C
Blood Res; 2014 Mar; 49(1):7-14. PubMed ID: 24724061
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells derived from pluripotent stem cells: Potential of large scale production.
Li Y; Liu M; Yang ST
World J Stem Cells; 2014 Jan; 6(1):1-10. PubMed ID: 24567783
[TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cell (iPSCs) and their application in immunotherapy.
Jiang Z; Han Y; Cao X
Cell Mol Immunol; 2014 Jan; 11(1):17-24. PubMed ID: 24336163
[TBL] [Abstract][Full Text] [Related]
20. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.
Zeng J; Wang S
Stem Cells Transl Med; 2014 Jan; 3(1):69-80. PubMed ID: 24292792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
